Diantha Duvall
CIK 1696784 · CFO · last filed 2026-07-09
Diantha Duvall is a CFO who has filed 26 SEC Form 4 insider transactions across 3 companies since 2017. The most recent filing, for CRIS, was dated Jul 9, 2026. Across all open-market trades the lifetime net is −$55.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BIVV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
128 SPRING ST. BLDG C. SUITE 500
LEXINGTON, MA 02421
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRIS | CFO | 3,885 | $0.38 | $1.5K | $0 | 7 | 2026-07-09 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | CHIEF FINANCIAL OFFICER | 75,388 | $0.00 | $45 | -$6.3K | 8 | 2022-06-03 |
| Bioverativ Inc. (BIVV) Delisted | Chief Accounting Officer | 0 | — | — | -$49.5K | 11 | 2018-03-08 |
Recent Filings
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-09 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2026-03-23 | CRIS | Conv (C) | +66,666 | $0 | EDGAR |
| 2026-03-18 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2025-01-30 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2024-05-23 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2023-01-24 | CRIS | Grant (A) | — | $0 | EDGAR |
| 2022-06-03 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Sell (S) | −1,355 | -$81 | EDGAR |
| 2022-05-26 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Sell (S) | −24,407 | -$1.9K | EDGAR |
| 2022-04-05 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Sell (S) | −963 | -$1.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.